Last reviewed · How we verify
Duration of eradication regimen
At a glance
| Generic name | Duration of eradication regimen |
|---|---|
| Also known as | 14 day treatment |
| Sponsor | Incheon St.Mary's Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer (PHASE2)
- Helicobacter Pylori Eradication Therapy for Immune Thrombocytopenia (ITP) Patients in Iraq (NA)
- Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia" (PHASE2)
- Efficacy of Different Durations of Dual and Quadruple Regimens for Helicobacter Pylori Eradication (PHASE4)
- Susceptibility-guided Bismuth Quadruple Therapy for Multiple-resistant Helicobacter Pylori Strains (PHASE4)
- 14-day Susceptibility-guided Bismuth Quadruple Therapy for Multiple Drug Resistant H. Pylori Infection (PHASE4)
- Helicobacter Pylori Eradication According to DPO-PCR Methods (K-CREATE) Study) (PHASE4)
- The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Duration of eradication regimen CI brief — competitive landscape report
- Duration of eradication regimen updates RSS · CI watch RSS
- Incheon St.Mary's Hospital portfolio CI